Clinical Trials · global
Nearly 80% reduction in Lp(a) fails to reduce cardiovascular events: pelacarsen falls short in Phase 3 trial
Following more than 8,300 people for nearly five years, a substantial improvement in a blood marker failed to translate into clinical benefit. The result is a setback for pelacarsen and leaves other trials to answer whether lowering Lp(a) can prevent heart attacks and strokes.
Can lowering a blood marker of risk actually prevent the next heart attack or stroke? Pelacarsen, developed to target lipoprotein(a) [Lp(a)], delivered two sharply different results in a large Phase 3 trial: Lp(a) levels fell by nearly 80%, but major cardiovascular events did not decline. Among participants with established cardiovascular disease, the treatment failed to demonstrate additional protection over nearly five years of follow-up.
Results from the Lp(a)HORIZON trial, led by Cleveland Clinic and funded by Novartis, were presented on November 7 at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine. According to information released by the medical center, the study randomly assigned 8,322 participants to pelacarsen or placebo, with monthly subcutaneous injections of 80 milligrams of the drug or matching placebo. The trial spanned 797 study sites in 42 countries.
Participants had Lp(a) levels of at least 70 mg/dL and a history of heart attack, stroke, or symptomatic peripheral artery disease, and were receiving established cardiovascular preventive treatment. After a median follow-up of 4.7 years, primary endpoint events occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group. This composite endpoint included cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization, with no overall reduction in risk observed.
The drug did change the marker it targeted. The American College of Cardiology (ACC) reported that after 12 months of pelacarsen treatment, Lp(a) had fallen by 78.4% from baseline, with a time-averaged reduction of 73.9% over approximately five years. However, among participants with higher baseline Lp(a) levels of at least 90 mg/dL, the primary endpoint occurred in 12.3% of both groups. Additional analyses released by the AHA also found no benefit for other cardiovascular outcomes or all-cause mortality.
Safety added considerations beyond efficacy. The AHA noted that flu-like symptoms, injection-site reactions, and adverse reactions leading to treatment discontinuation were more common in the pelacarsen group. Anaphylaxis occurred in 19 participants in that group, with no cases in the placebo group; none of these allergic reactions were fatal.
Lp(a) is a lipoprotein particle with characteristics similar to low-density lipoprotein. Its levels are largely genetically determined, and elevated levels are associated with atherosclerosis and cardiovascular risk. Pelacarsen uses synthetic nucleic acid that enters liver cells to inhibit Lp(a) production. These results show that even a sustained, substantial reduction in this marker must still be supported by evidence from clinical events to establish the treatment's value. Improvements in laboratory values cannot be directly equated with a reduction in disease risk.
This trial cannot yet answer whether all strategies to lower Lp(a) are effective. The ACC cited the research team's explanation that all participants already had cardiovascular disease, so the results cannot address the effect of intervening before a first event. Therapies with other mechanisms of action also require their own outcomes trials. Pelacarsen's failure to demonstrate benefit in this trial leaves more specific research questions: whether different drugs, different degrees of reduction, and different timing of intervention can translate lower Lp(a) levels into fewer cardiovascular events.